pipette
ENEnglish

Engineered endocrine objects tolerate hypoxia in macroencapsulation devices and enable subcutaneous engraftment in diabetic mice

K. Wang, K. Okada, M. Jin, J. Deng, B. Wang, J. A. Flanders, P. L. Tran, M. Lee, M. Ma

PreprintAfirmaciones fuertes, leer con cuidadoUso en el mundo real

En palabras de los autores

Islet encapsulation has been pursued for decades as a potential immunosuppression-free transplantation strategy to treat type 1 diabetes (T1D). The encapsulation device protects islets from immune cell-contact mediated killing, but it also prevents vascular penetration and intra-islet vascularization, leading to poor mass transfer and islet central necrosis. In healthy pancreas, islets with sizes > ~40 m are vascularized while non-islet endocrine cell clusters below ~40 m exist without internal capillaries. Here, we developed scalable and reproducible engineered endocrine objects (EEOs) as small as ~47 m by mesh-induced fragmentation of native islets, followed by a recovery culture. Under hypoxic culture condition (1% O2 for 24 hours), EEOs showed enhanced viability of >90%, compared to 49% for the native islet control. With a flat, thin (0.5-mm-thick) alginate-based macroencapsulation device, rat EEOs at a marginal dose of 300 islet equivalents (IEQ) achieved glycemic control for over 5 weeks in the challenging, hypoxic subcutaneous space of immunocompetent diabetic mice. The engrafted mice displayed near-physiological glycemic profiles upon glucose challenge, and the retrieved EEOs showed enhanced viability with significantly reduced central necrosis compared with native islets. Overall, engineering hypoxia-resistance into cellular products mitigates intrinsic constraints of encapsulation devices, offering a promising strategy for convenient, immunosuppression-free subcutaneous islet transplantation.

Resultado principalEl resumen no menciona limitaciones.

Apareció: viernes, 13 de noviembre. bioRxiv. Preprint, todavía sin revisión por pares.

DOI: 10.64898/2026.11.10.765512